Evaluate Aerobic Exercise on Myocardial Fibrosis and Intestinal Flora in Dilated Cardiomyopathy Diagnosed First Time.

Cardiac Rehabilitation Clinical Trial

Official title:

Study on the Changes of Intestinal Flora and Cardiac Fibrosis in Patients With Dilated Cardiomyopathy Diagnosed for the First Time by Sports Rehabilitation

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06039969
• Other study ID #: 20230911
• Status: Recruiting
• Start date: October 1, 2023
• Est. completion date: October 1, 2025

Study information

• Verified date: September 2023
• Source: Nanjing Medical University
• Contact: Jin Geng, MD
• Phone: +86-17753124846
• Email: gj885258[@]163.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

To invegstive the Changes of Intestinal Flora and the improvements of Cardiac Fibrosis in Patients With Dilated Cardiomyopathy Diagnosed for the First Time by heart Rehabilitation

Description:

Previous studies have confirmed that Aerobic exercise rehabilitation can reduce the rate of readmission of patients with heart failure and improve their cardiopulmonary endurance and exercise ability. However, whether aerobic exercise rehabilitation can inhibit myocardial fibrosis or delay the progress of fibrosis in patients with heart failure has not been reported. At the same time, some studies have shown that the change of intestinal microbial flora may promote the progress of heart failure, and regular aerobic exercise will also lead to the change of intestinal microbial flora, but whether aerobic exercise rehabilitation can improve intestinal microbial flora in patients with dilated cardiomyopathy has not been reported. In our study, patients who were hospitalized for heart failure for the first time and were finally diagnosed with dilated cardiomyopathy were recruited. Recruited patients will enter the routine cardiac rehabilitation process and make an individualized aerobic exercise plan according to the cardiopulmonary exercise test. Cardiac MRI and intestinal microflora changes will be evaluated.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: October 1, 2025
• Est. primary completion date: October 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• 1?Patients hospitalized for the first time because of heart failure 2?The patient who was definitely diagnosed as dilated cardiomyopathy for the first time

Exclusion Criteria:

• 1?Other types of cardiomyopathy 2?Has been diagnosed as dilated cardiomyopathy. 3?malignant tumor 4?acute infection 5?Cannot perform cardiopulmonary exercise test.

Related Conditions & MeSH terms

• Cardiac Rehabilitation
• Cardiomyopathies
• Cardiomyopathy, Dilated
• Fibrosis
• Myocardial Fibrosis

Locations

Country	Name	City	State
China	Huai'An First People'S Hospital	Huai'an	Jiangsu

Sponsors (1)

Lead Sponsor	Collaborator
Nanjing Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	cardiac fitiness	Assessment of caridac fitness based on ardiopulmonary exercise test	first admission six months one year
Primary	myocardial fibrosis	Assessment of myocardial fibrosis based on cardiac MRI examination	first admission six months one year
Secondary	Bacterial spectrum of intestine	Assessment of Bacterial spectrum of intestine based on Patient feces sequencing	first admission six months one year